The top decile of private European money raisers elevated their game in 2013, averaging $63.3 million vs. $49.7 million in 2012, and better than matching the average of $62.3 million raised by the top 10% of private biotechs in the U.S. last year. The average raised by top U.S. teams also was down from $87.4 million in 2012.

Overall, private European biotechs that raised money last year averaged $15 million, up from